916213-60-0

Basic information

• Product Name: 4-bromo-3-hydroxybenzonitrile
• Synonyms: 4-bromo-3-hydroxybenzonitrile
• CAS NO: 916213-60-0
• Molecular Formula: C7H4BrNO
• Molecular Weight: 198.01676
• Mol File: 916213-60-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 260.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.79±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 7.04±0.10(Predicted)
• CAS DataBase Reference: 4-bromo-3-hydroxybenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-3-hydroxybenzonitrile(916213-60-0)
• EPA Substance Registry System: 4-bromo-3-hydroxybenzonitrile(916213-60-0)

Safety Data

• Hazardous Substances Data: 916213-60-0(Hazardous Substances Data)

Usage

General Description

4-bromo-3-hydroxybenzonitrile is a chemical compound that contains a benzene ring with a hydroxyl group and a nitrile group attached to it, as well as a bromine atom at the 4th position. It is a white to off-white solid that is primarily used in organic synthesis and pharmaceutical research. 4-bromo-3-hydroxybenzonitrile is known for its use in the production of various pharmaceuticals, as well as in the synthesis of other organic compounds. It is also used as an intermediate in the manufacturing of agrochemicals and other fine chemicals. Additionally, 4-bromo-3-hydroxybenzonitrile is a versatile building block in the synthesis of many other biologically active compounds and is often used as a reagent in chemical reactions.

Upstream product

• 120315-65-3 4-bromo-3-methoxy-benzonitrile 
• 133059-44-6 4-bromo-3-fluorobenzonitrile 
• 873-62-1 m-cyanophenol 

Relevant articles and documents

Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase

The inhibition of 11β-hydroxylase is a promising strategy for the treatment of Cushing's syndrome, in particular for the recurrent and subclinical cases. To achieve proof of concept in rats, efforts were paid to identify novel lead compounds inhibiting both human and rat CYP11B1. Modifications on a potent promiscuous inhibitor of hCYP11B1, hCYP11B2 and hCYP19 (compound IV) that exhibited moderate rCYP11B1 inhibition led to compound 8 as a new promising lead compound. Significant improvements compared to starting point IV were achieved regarding inhibitory potency against both human and rat CYP11B1 (IC50 values of 2 and 163 nM, respectively) as well as selectivity over hCYP19 (IC50 Combining double low line 1900 nM). Accordingly, compound 8 was around 7-and 28-fold more potent than metyrapone regarding the inhibition of human and rat CYP11B1 and exhibited a comparable selectivity over hCYP11B2 (SF of 3.5 vs 4.9). With further optimizations on this new lead compound 8, drug candidates with satisfying profiles are expected to be discovered.

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.